[Federal Register Volume 77, Number 85 (Wednesday, May 2, 2012)]
[Notices]
[Page 26014]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-10547]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Prospective Grant of Exclusive License: P4 Peptide From 
Streptococcus Pneumoniae

AGENCY: Technology Transfer Office, Centers for Disease Control and 
Prevention (CDC), Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 
CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention 
(CDC), Technology Transfer Office, Department of Health and Human 
Services (DHHS), is contemplating the grant of a worldwide, exclusive 
license (excluding the nonexclusively licensed field of use entitled 
``Use of P4 as either a carrier and/or immunoenhancer in a 
polysaccharide vaccine conjugate for prevention of Streptococcus 
pneumonia infection in humans'') to practice the inventions embodied in 
the patent application referred to below to Viper Therapeutics, having 
a place of business in Atlanta, Georgia. The patent rights in these 
inventions have been assigned to the government of the United States of 
America. The patent(s) to be licensed are:

    ``U.S. Patent 7,919,104 entitled ``Functional Epitopes of 
Streptococcus Pneumoniae PsaA Antigen and Uses Thereof,'' filed 7/
18/2008, claiming priority to U.S. Provisional Patent Application 
No. 60/682,495, filed 5/19/2005, and all related continuing and 
foreign patents/patent applications for the technology family. CDC 
Technology ID No. I-030-04.

    Status: Issued.
    Priority Date: 5/19/2005.
    Issue Date: 4/5/2011.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.

Technology

    This technology consists of a P4 peptide which contains functional 
epitopes of the PsaA protein of Streptococcus pneumoniae. This 
technology also includes an antibody that can bind to the epitopes of 
the defined peptides. The technology is a complete kit that includes 
two vaccines comprised of two separate peptides, a pharmaceutical 
carrier for each vaccine, methods of using the peptides and antibodies, 
and diagnostic kits comprising a P4 peptide.

ADDRESSES: Requests for a copy of this patent, inquiries, comments, and 
other materials relating to the contemplated license should be directed 
to Donald Prather, J.D., Ph.D., Technology Licensing and Marketing 
Specialist, Technology Transfer Office, Centers for Disease Control and 
Prevention (CDC), 4770 Buford Highway, Mailstop K-79, Atlanta, GA 
30341, Telephone: (770) 488-8612; Facsimile: (770) 488-8615. 
Applications for a license filed in response to this notice will be 
treated as objections to the grant of the contemplated license. Only 
written comments and/or applications for a license which are received 
by CDC within thirty days of this notice will be considered. Comments 
and objections submitted in response to this notice will not be made 
available for public inspection, and, to the extent permitted by law, 
will not be released under the Freedom of Information Act, 5 U.S.C. 
552.

    Dated: April 23, 2012.
Tanja Popovic,
Deputy Associate Director for Science, Centers for Disease Control and 
Prevention.
[FR Doc. 2012-10547 Filed 5-1-12; 8:45 am]
BILLING CODE 4163-18-P